stocks logo

TOI Earnings

Oncology Institute Inc
$
4.110
-0.13(-3.066%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

Earning Analysis

Welcome to our in-depth analysis of Oncology Institute Inc(TOI) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Oncology Institute Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.

Earnings Forecast

Revenue
EPS
Currency: USD
Actual
Estimate

Surprise Analysis

Name
EPS
Revenue
Price Reaction
Fiscal QuarterEarning DateTimeEstimateActualSurprise%EstimateActualSurprise%1D5D
FY2025Q22025-08-13After Hours-0.14--113.48M----
-2025-05-14After Hours--0.18--104.41M-+28.27+17.30
FY2024Q22024-08-13After Hours-0.15-0.17-13.33103.31M98.58M-4.58-18.18-27.27
FY2024Q12024-05-14--0.12-0.22-83.3395.17M94.67M-0.52+3.57-29.80
FY2023Q42024-03-27--0.11-0.21-90.9182.04M85.79M+4.57+8.88-11.83
FY2023Q32023-11-08--0.13-0.19-46.1574.66M82.04M+9.87+5.75+38.51
FY2023Q22023-08-08--0.17-0.19-11.7673.79M80.22M+8.72+4.12-11.34
-2023-03-09--0.18-0.16+11.11----11.35-53.05
-2022-11-09--0.16-0.17-6.25----4.32-37.04

TOI Earnings Analysis

Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Oncology Institute Inc reported performance for FY2025Q2, announced on 2025-08-13. The company achieved an EPS of , compared to analyst estimates of -0.14 by % . Revenue for the quarter reached 0.00 compared to expectations of 113.48M by % .
The stock price reacted with a % one-day change and a % five-day change following the earnings release. These movements reflect market reaction in Oncology Institute Inc growth trajectory and strategic initiatives.

TOI Earnings Forecast

Looking ahead, Oncology Institute Inc(TOI) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2024/Q3 project quarter revenue of 107.54M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 1.03%, while EPS estimates have been No Change by 0%. For the upcoming Q2 2025, revenue estimates have been adjusted Revise Upward by 1.79% . These revisions correlate with a 55.09% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Oncology Institute Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

Estimate Revision

The chart shows the correlation between TOI's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.03%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Upward
up Image
+1.79%
In Past 3 Month
Stock Price
Go Up
up Image
+55.09%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
--
Revenue Estimate-Annual FY 2025:466.82M
--
EPS Estimate-Annual FY 2025:-0.16
Stock Price4.11

TOI Revenue and EPS Performance: A Historical Perspective

Oncology Institute Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-13,After Hours):
EPS: (Actual) vs.-0.14 (Estimate) (%)
Revenue: 0.00 (Actual) vs. 113.48M (Estimate) (%)
Price Reaction: %(1-Day), %(5-Day)
(2025-05-14,After Hours):
EPS: -0.18 (Actual) vs. (Estimate) (%)
Revenue: 104.41M (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 28.27%(1-Day), 17.30%(5-Day)
FY2024Q2 (2024-08-13,After Hours):
EPS: -0.17 (Actual) vs.-0.15 (Estimate) (-13.33%)
Revenue: 98.58M (Actual) vs. 103.31M (Estimate) (-4.58%)
Price Reaction: -18.18%(1-Day), -27.27%(5-Day)
Earnings Reaction
The chart below shows how TOI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TOI sees a +10.67% change in stock price 10 days leading up to the earnings, and a -21.23% change 10 days following the report. On the earnings day itself, the stock moves by +1.19%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed 28.27% on the day following the earnings release and then changed by 35.44% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

Transcript Summary

Oncology Institute Inc (TOI) Q1 2025 Earnings Call Summary
Positive
2025-05-14
The earnings call reveals strong financial performance with a 44% increase in gross profit and improved EBITDA, indicating operational efficiency. The company has a robust pipeline, especially in fee-for-service revenue, and is on track for cash flow positivity by Q4 2025. Despite some uncertainties in contract terminations, the overall guidance is optimistic, with significant revenue growth expected. The positive sentiment is further supported by improved margins and cost optimization efforts, suggesting a favorable short-term stock price movement.
Oncology Institute Inc (TOI) Q1 2025 Earnings Call Summary
Positive
2025-05-14
The earnings call summary indicates strong financial performance with 21% revenue growth, improved gross profit, and reduced losses. New contracts and cost optimization strategies further strengthen the outlook. Although there are some risks in contractual stability and financial performance, management appears confident in their ability to mitigate these. The Q&A section did not reveal significant negative trends. Overall, the positive financial results and guidance, alongside operational improvements and a commitment to shareholder value, suggest a positive stock price movement in the short term.
Oncology Institute Inc (TOI) Q4 2024 Earnings Call Summary
Neutral
2025-03-27
The earnings call presents mixed signals. While revenue and net loss improved, gross profit declined, and adjusted EBITDA worsened. The Q&A highlights growth potential in capitation contracts and new markets like Florida, but management's reluctance to provide specific guidance raises concerns. The private placement and debt conversion improve financial flexibility, but regulatory and competitive pressures pose risks. Overall, the positive and negative factors balance each other, leading to a neutral stock price prediction.
Oncology Institute Inc (TOI) Q4 2024 Earnings Call Summary
Neutral
2025-03-25
The earnings call revealed mixed signals: revenue growth and debt reduction are positive, but gross profit decline and cash flow risks are concerning. The Q&A highlighted optimism for 2025, particularly in patient services, yet lacked specific guidance. The private equity placement and debt conversion are neutral factors. Given these elements, the prediction leans towards a neutral stock price movement over the next two weeks.
Oncology Institute Inc (TOI) Q4 2024 Earnings Call Summary
Neutral
2025-03-25
The earnings call presents mixed signals. Revenue growth and debt reduction are positive, but gross profit decline and negative free cash flow outlook raise concerns. The private placement and debt conversion suggest financial restructuring, which can be seen negatively. Q&A reveals growth potential in new markets but lacks specific guidance, adding uncertainty. Overall, the positives and negatives balance out, leading to a neutral sentiment.
Oncology Institute Inc (TOI) Q4 2024 Earnings Call Summary
Neutral
2025-03-25
The earnings call presents a mixed picture: strong revenue growth (17% YoY) and improved operational efficiency are positive signs, but the decline in gross profit margins and increasing adjusted EBITDA losses are concerning. Debt management efforts, including equity conversion, are positive but highlight financial risks. The lack of specific guidance in some areas and reliance on new contracts for growth add uncertainty. Overall, the sentiment is balanced, with positive and negative factors offsetting each other, leading to a neutral stock price prediction.
The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Summary
Neutral
2024-11-14
The earnings call summary presents a mixed outlook. Positive aspects include increased revenue, improved gross margins, and new contracts, but these are countered by compliance risks with NASDAQ and ongoing losses. The absence of significant questions in the Q&A suggests no major concerns, but the stock price compliance issue and lack of strong earnings guidance temper enthusiasm. With no clear market cap, the reaction is likely neutral, balancing the positives and negatives.

FAQ

arrow icon

What were the key highlights of TOI’s latest earnings report for FY2025Q2?

TOI reported its FY2025Q2 earnings on 2025-08-13, showcasing a revenue of 0.00 against an estimate of 113.48M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.14 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.
arrow icon

How did TOI’s stock price react after the FY2025Q2 earnings release?

arrow icon

What are the revenue and EPS estimates for TOI for 2024/Q3?

arrow icon

How does TOI’s stock price correlate with earnings forecast revisions?

arrow icon

What should investors expect from TOI’s next earnings report?

arrow icon

What is the sentiment in Oncology Institute Inc (TOI) Q1 2025 Earnings Call Summary?